https://www.selleckchem.com/pr....oducts/orforglipron-
Neoadjuvant chemoradiotherapy followed by surgery establishes a considerable pathologic complete response (pCR) in EC. The aim was to determine site of residual tumor and its prognostic impact. High rates of residual tumor in the adventitial region even inside the radiation fields will influence current decision-making. We evaluated resection specimens with marked target fields from 151 consecutive EC patients treated with carboplatin/paclitaxel and 41.4Gy between 2009 and 2018. In radically resected (R specimens 19.8%
Like
Comment
Share
